Landmark Consensus Defines Safe Deprescribing of Psychotropic Meds for Mood Disorders

New ASCP guidelines provide clinicians with evidence-based framework to optimize long-term pharmacotherapy and minimize medication burden.

Apr. 3, 2026 at 6:06pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the internal structures of a human brain in shades of blue and grey, conceptually representing the complex neural networks and chemical pathways involved in mood regulation.An X-ray view of the brain's intricate circuitry offers insights into the complex neurological underpinnings of mood disorders and the need for thoughtful medication management.Brentwood Today

A newly published study by a Task Force from the American Society of Clinical Psychopharmacology (ASCP) offers a critical framework to guide clinicians in the complex and under-defined area of deprescribing psychotropic medications in patients with mood disorders. Using a rigorous Delphi consensus process involving 45 international experts, the study establishes evidence-informed clinical principles to help clinicians strike the right balance between therapeutic benefit and medication burden for patients with major depressive disorder and bipolar disorder.

Why it matters

Despite widespread use of long-term pharmacotherapy in mood disorders, clinicians have historically lacked clear guidance on when continued treatment may no longer be beneficial or even harmful. This landmark study directly addresses that gap by identifying clinical scenarios where deprescribing is appropriate, emphasizing that deprescribing is not synonymous with undertreatment, but rather reflects thoughtful, patient-centered medication optimization.

The details

The study achieved consensus on 63% of evaluated clinical scenarios, underscoring both the emerging clarity and the persistent uncertainty in this domain. Key findings include that experts agree antidepressants should be discontinued when trials yield minimal benefit, initial response cannot be recaptured after relapse, and multiple overlapping agents are used unnecessarily. Indefinite maintenance treatment is often warranted for recurrent major depression. The panel strongly endorsed deprescribing antidepressants in bipolar disorder when rapid cycling, mixed features, or mania/hypomania emerge. For nonpsychotic mood disorders, experts favor discontinuing antipsychotics when significant weight gain, metabolic issues, or tardive dyskinesia occur. There was strong agreement that benzodiazepines and 'Z-drugs' should be deprescribed within 1-3 months whenever possible.

  • The ASCP Task Force published an earlier consensus statement on general principles of deprescribing psychotropic medications earlier this year.
  • This new study was published on April 3, 2026.

The players

American Society of Clinical Psychopharmacology (ASCP)

A professional organization dedicated to advancing the science, practice, and education of clinical psychopharmacology to improve the health and well-being of patients.

ASCP Task Force

A group of 45 international experts who used a rigorous Delphi consensus process to establish the evidence-informed clinical principles in this study.

Got photos? Submit your photos here. ›

What’s next

The authors underscore the urgent need for prospective deprescribing trials, predictors of successful medication discontinuation, and better characterization of patient subgroups who may benefit from reduced pharmacotherapy.

The takeaway

This landmark consensus study represents a major step forward in providing clinicians with evidence-based guidance on when and how to safely deprescribe psychotropic medications for patients with mood disorders, emphasizing the importance of individualized, patient-centered medication optimization.